{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:00:21Z","timestamp":1761746421415,"version":"build-2065373602"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To provide an updated overview of optimal antibiotic duration in ventilator-associated pneumonia (VAP), integrating guideline recommendations, clinical evidence, and expert opinion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>A randomized controlled trial, retrospective studies and meta-analyses support shorter (\u22647\u20138-day) regimens for immunocompetent patients with VAP, reducing toxicity and, potentially, resistance development without compromising outcomes. However, while short-course regimens are increasingly supported, recent trials of newer agents often report durations &gt;7\u200adays, reflecting real-world challenges in resistant pathogens and trial design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>VAP remains the leading healthcare-associated infection in intensive care units (ICUs), related to worse outcomes and contributing substantially to antimicrobial use. Historically, prolonged antibiotic courses (\u226510\u201314) were standard, particularly for cases involving multidrug-resistant (MDR) or extensively drug-resistant (XDR) organisms. This review synthesizes current evidence supporting shorter course therapy for VAP (\u22647\u20138\u200adays), emphasizing the importance of clinical response and individualization. While guideline convergence on 7\u20138\u200adays has grown, exceptions apply for specific pathogens (e.g., nonfermenters, MDR or XDR organisms), bacteremia, slow response, or structural lung disease. Biomarkers like procalcitonin may assist in select cases but lack VAP-specific validation. Regular reassessment is essential to balance efficacy with stewardship. Evidence gaps remain for immunocompromised patients and ultra-short regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001298","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:00:25Z","timestamp":1751875225000},"page":"520-528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ventilator-associated pneumonia: how long is long enough?"],"prefix":"10.1097","volume":"31","author":[{"given":"Despoina","family":"Koulenti","sequence":"first","affiliation":[{"name":"Critical Care Department, King's College Hospital, NHS Foundation Trust, London, United Kingdom"},{"name":"UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia"},{"name":"School of Health Sciences, University of Ioannina, Ioannina"},{"name":"Medical School, University of Thessaly, Larissa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Panagiota","family":"Almyroudi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Katsounas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Infectious Diseases and Critical Care Division, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(23)00418-6","article-title":"Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, noninferiority trial","volume":"12","author":"Mo","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.eclinm.2023.101880","article-title":"Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Daghmouri","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"154346","DOI":"10.1016\/j.jcrc.2023.154346","article-title":"Short-course versus prolonged-course antibiotic regimens for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Cheema","year":"2023","journal-title":"J Crit Care"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","author":"Daneman","year":"2025","journal-title":"N Engl J Med"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmi.2024.05.003","article-title":"Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a posthoc analysis of a randomized clinical trial","volume":"30","author":"Dinh","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13054-024-05180-y","article-title":"D-PRISM: a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care","volume":"28","author":"Reyes","year":"2024","journal-title":"Crit Care"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00134-022-06690-5","article-title":"Comparison of 8 versus 15\u200adays of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial","volume":"48","author":"Bougl\u00e9","year":"2022","journal-title":"Intensive Care Med"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s15010-024-02358-y","article-title":"Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007","volume":"52","author":"Rademacher","year":"2024","journal-title":"Infection"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.21037\/jtd.2019.06.09","article-title":"Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)","volume":"11","author":"Shi","year":"2019","journal-title":"J Thorac Dis"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13613-018-0444-0","article-title":"Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU","volume":"8","author":"Leone","year":"2018","journal-title":"Ann Intensive Care"},{"issue":"(7 Suppl)","key":"R14-20251029","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jiac.2015.12.019","article-title":"JAID\/JSC guidelines for the treatment of respiratory infectious diseases: the Japanese Association for Infectious Diseases\/Japanese Society of Chemotherapy - the JAID\/JSC guide to clinical management of infectious disease\/guideline-preparing committee research","volume":"22","author":"Mikasa","year":"2016","journal-title":"J Infect Chemother"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"e050105","DOI":"10.1136\/bmjopen-2021-050105","article-title":"Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial","volume":"11","author":"Mo","year":"2021","journal-title":"BMJ Open"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"De Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R19-20251029","first-page":"CD007498","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"10","author":"Schuetz","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.chest.2018.12.029","article-title":"Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis","volume":"155","author":"Pepper","year":"2019","journal-title":"Chest"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1186\/s12879-024-09600-w","article-title":"Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better?","volume":"24","author":"Truong","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"e077428","DOI":"10.1136\/bmjopen-2023-077428","article-title":"Association of antibiotic duration and all-cause mortality in a prospective study of patients with ventilator-associated pneumonia in a tertiary-level critical care unit in Southern India","volume":"14","author":"Stanley","year":"2024","journal-title":"BMJ Open"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QCO.0000000000000977","article-title":"Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains","volume":"36","author":"Koulenti","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15\u200adays of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, noninferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1 a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, noninferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, noninferiority clinical tri","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/antibiotics13070629","article-title":"Novel antibiotics for gram-negative nosocomial pneumonia","volume":"13","author":"Almyroudi","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2047-2994-2-31","article-title":"Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum","volume":"2","author":"Huttner","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1097\/01.CCM.0000277042.31524.66","article-title":"Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia","volume":"35","author":"Agbaht","year":"2007","journal-title":"Crit Care Med"},{"key":"R38-20251029","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.01021-12","article-title":"Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study","volume":"57","author":"Chong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-20251029","first-page":"2556","article-title":"Staphylococcus aureus ventilator-associated pneumonia: a study of bacterio-epidemiological profile and virulence factors","volume":"78","author":"Tilouche","year":"2021","journal-title":"CurrMicrobiol"},{"key":"R40-20251029","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1378\/chest.13-0076","article-title":"Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis","volume":"144","author":"Dimopoulos","year":"2013","journal-title":"Chest"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/antibiotics13111078","article-title":"Duration of antimicrobial treatment in adult patients with pneumonia: a narrative review","volume":"13","author":"Dimopoulou","year":"2024","journal-title":"Antibiotics (Basel)"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:49:10Z","timestamp":1761734950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001298","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"type":"print","value":"1070-5295"},{"type":"electronic","value":"1531-7072"}],"subject":[],"published":{"date-parts":[[2025,7,4]]}}}